|Slideshows|December 23, 2019

Exploring the Proactive Model

How much do you know about the innovative Proactive Consultation-Liaison (C-L) Psychiatry model? Learn more and test your knowledge in this interactive quiz.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

ByJessica Walters

October 23rd 2025

Childhood-Onset Fluency Disorder: Perspectives on Comorbid Anxiety and Stuttering

ByYoshikazu Kikuchi, MD, PhD,Heidi Anne Duerr, MPH

September 17th 2025

Genetic and Comorbidity Studies Suggest New Model for Understanding Stuttering

ByHeidi Anne Duerr, MPH

September 14th 2025

ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment

ByDavid N. Osser, MD

June 17th 2025

Here are highlights from the week in Psychiatric Times.

The Week in Review: May 13-17

ByErin O'Brien

May 18th 2024

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Exploring the Proactive Model

Newsletter

Related Content

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

Childhood-Onset Fluency Disorder: Perspectives on Comorbid Anxiety and Stuttering

Genetic and Comorbidity Studies Suggest New Model for Understanding Stuttering

ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment

The Week in Review: May 13-17

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

What Happened to Psychopathology?